BioPorto
1.484
DKK
-6.78 %
BIOPOR
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
17 following
-6.78%
-11.67%
-23.03%
-27.61%
-29%
-36.45%
-41.77%
-36.22%
-37.71%
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read moreMarket cap
637.63M DKK
Turnover
2.63M DKK
Revenue
30.96M
EBIT %
-197.58 %
P/E
-
Dividend yield-%
-
Coverage
Latest research
Latest analysis report
Released: 2024-12-10
ShowingAll content types
Bioporto (One-pager): Emerging as a Diagnostic growth company
BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Grant of Warrants
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital
Bioporto: Indgår partnerskab med Beckman Coulter om NGAL Tests til akut nyreskade
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests
Bioporto: Wrap up from yesterday's event
BioPorto - Building the Global Commercial Platform
Bioporto: AKI adult study - insights
Dagens aktienyheder 15/08: TORM, Spar Nord, Skjern Bank, MapsPeople, ExpreS2ion Biotechnologies, Ascelia Pharma og BioPorto
BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024
BioPorto: Potential for labelling expansion of NGAL test
Grant of Warrants
Managers’ transactions
Changes of number of shares and votes in BioPorto A/S
Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
HCA Capital: Wrap up from 2024 Life Science seminar
